Cita APA (7a ed.)

TJE, T., A, D., S, S., & M, L. (2021). Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press.

Cita Chicago Style (17a ed.)

TJE, Tarigan, Dwijayanti A, Setyowati S, y Louisa M. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.

Cita MLA (8a ed.)

TJE, Tarigan, et al. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.